XWELL Receives Nasdaq Bid-Price Deficiency Notice, Has Until April 5, 2027 to Cure
XWEL has more than doubled off its 52-week low of $0.255.
Summary
XWELL received a Nasdaq notice that its stock has traded below $1.00 for 30 consecutive business days, giving it until April 5, 2027 to regain compliance — likely via a reverse split — just two weeks before the October 28 vote on the $13 million asset sale.
Key Events · Legal and Risk Events · XWEL
-
Nasdaq Bid-Price Deficiency Notice
Nasdaq notified XWELL on October 7, 2026 that its common stock had closed below the $1.00 minimum bid price for the 30 consecutive business days from August 25 through October 6, 2026, breaching Listing Rule 5550(a)(2).
-
180-Day Cure Window to April 5, 2027
The company must post ten consecutive closes at or above $1.00 by April 5, 2027; any reverse split used to cure the deficiency must be completed at least ten business days before that deadline.
-
$0.10 Trigger for Immediate Delisting Action
If the closing bid sits at $0.10 or less for ten consecutive trading days during the compliance period, Nasdaq will issue a Staff Delisting Determination without waiting out the 180 days.
-
Second Compliance Period Possible
An additional 180 calendar days may be available if XWELL meets the market value of publicly held shares test and all other initial listing standards, and notifies Nasdaq in writing of its cure plan.
Analysis · XWEL · Trade & Services
The listing is now under formal threat: XWELL closed below $1.00 for 30 straight business days (Aug 25 - Oct 6, 2026) and received a Nasdaq staff notice on October 7. With the stock at $0.7165 today, the gap to the $1.00 threshold is wide and the clock is running. Compliance requires ten consecutive closes at or above $1.00 before April 5, 2027, and any reverse split would have to be completed at least ten business days before that date. The harsher clause is the $0.10 trigger: ten consecutive trading days at or below a dime and Nasdaq issues a Staff Delisting Determination with no 180-day grace. This lands two weeks before the October 28 shareholder vote on the $13 million sale of XpresSpa and XpresTest, so the company is simultaneously asking holders to approve a business exit while its listing is under formal threat. A reverse split is the obvious mechanical fix, but it would need shareholder authorization and would come on top of the five material weaknesses and $2.24 million quarterly loss previously disclosed in the Q2 10-Q.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XWEL was trading at $0.72 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $0.26 to $2.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.